Recombinant Human IL-1 RAcP/IL-1 R3 His Avi-tag Protein, CF

When Recombinant Human IL‑1 RI Fc Chimera Protein (11085-RI) is immobilized at 2 µg/mL (100 µL/well) in the presence of Recombinant Human IL‑1 beta /IL‑1F2 Protein (201-LB), it binds to Biotinylated Recombinant Human IL‑1 RAcP/IL‑1 R3 His-tag Avi-tag Protein (Catalog # AVI9176) with an ED50 of 50.0-400 ng/mL.

2 μg/lane of Recombinant Human IL-1 RAcP/IL-1 R3 His-tag Avi-tag Protein (Catalog # AVI9176) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 59-65 kDa.

• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human IL-1 RAcP/IL-1 R3 His Avi-tag Protein, CF Summary

• Additional Information: Biotinylated
• Details of Functionality: Measured by its binding ability in a functional ELISA. When Recombinant Human IL-1 RI Fc Chimera (Catalog # 11085-RI) is immobilized at 2 µg/mL (100 µL/well) in the presence of Recombinant Human IL-1 beta /IL-1F2 (Catalog # 201-LB) , it binds to Biotinylated Recombinant Human IL-1 RAcP/IL-1 R3 His-tag Avi-tag (Catalog # AVI9176) with an ED₅₀ of 50.0-400 ng/mL.
• Source: Chinese Hamster Ovary cell line, CHO-derived human IL-1 RAcP/IL-1 R3 protein
  

  Human IL-1 RAcP/IL-1 R3 (Ser21-Glu359) Accession # Q9NPH3.2	6-His tag	Avi-tag
  N-terminus		C-terminus

• Accession #: Q9NPH3.2
• N-terminal Sequence: Ser21
• Structure / Form: Biotinylated via Avi-tag
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 42 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 59-65 kDa, under reducing conditions.

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 500 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human IL-1 RAcP/IL-1 R3 His Avi-tag Protein, CF

• C3orf13IL-1RAcPIL1R3Interleukin-1 receptor 3
• FLJ37788
• IL-1 R3
• IL-1 RAcP
• IL-1 receptor accessory protein
• IL-1R3
• IL-1R-3
• IL1RAcP
• IL-1RAcP
• IL1RAP
• interleukin 1 receptor accessory protein
• interleukin-1 receptor accessory protein beta
• interleukin-1 receptor accessory protein

Background

IL-1 Receptor Accessory Protein (IL-1 RAcP), also known as IL-1 R3, is a ubiquitously expressed 70-90 kDa member of the Interleukin-1 receptor family of proteins (1). It serves as a non-ligand-binding component of the receptors for IL-1 alpha , IL-1 beta , IL-33, and IL-36 (2-4). It is a subunit of the functional signaling complex with IL-1 RI and associates with IL-1 RII in a non-signaling receptor complex (2, 5). In addition, it interacts with ST2/IL-1 R4 on mast cells and Th2 cells to create a functional IL-33 receptor complex (3). IL-1 RAcP also functions as a co-receptor for IL-36 alpha /IL-1F6, IL-36 beta /IL-1F8, and IL-36 gamma /IL-1F9 (4). Mature human IL-1 RAcP consists of a 347 amino acid (aa) extracellular domain (ECD) with three Ig-like domains, a 21 aa transmembrane segment, and a 182 aa cytoplasmic domain (2). Within the ECD, human IL-1 RAcP shares 86% aa sequence identity with mouse and rat IL-1 RAcP. Alternative splicing generates two secreted decoy receptor isoforms and an isoform with a substituted cytoplasmic domain (6-8). When present with soluble IL-1 RII, soluble IL-1 RAcP increases the IL-1 binding affinity of IL-1 RII more than 100-fold, thus neutralizing the effects of IL-1 (9). Neuronal IL-1 RAcP interacts trans-synaptically with PTP sigma and can induce excitatory pre- and post-synaptic development (10). . Our Avi-tag Biotinylated Human IL-1 RAcP features biotinylation at a single site contained within the Avi-tag, a unique 15 amino acid peptide. Protein orientation will be uniform when bound to streptavidin-coated surface due to the precise control of biotinylation and the rest of the protein is unchanged so there is no interference in the protein's bioactivity.

1. Boraschi, D. and A. Tagliabue (2013) Semin. Immunol. 25:394.
2. Greenfeder, S.A. et al. (1995) J. Biol. Chem. 270:13757.
3. Chackerian, A.A. et al. (2007) J. Immunol. 179:2551.
4. Towne, J.E. et al. (2004) J. Biol. Chem. 279:13677.
5. Lang, D. et al. (1998) J. Immunol. 161:6871.
6. Lu, H.-L. et al. (2008) Mol. Immunol. 45:1374.
7. Jensen, L.E. et al. (2000) J. Immunol. 164:5277.
8. Jensen, L.E. and A.S. Whitehead (2003) Cell. Signal. 15:793.
9. Smith, D.E. et al. (2003) Immunity 18:87.
10. Yoshida, T. et al. (2012) J. Neurosci. 32:2588.

Bioinformatics

• Uniprot:
  • Q9NPH3.2()